Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G versus MYCOSTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G versus MYCOSTATIN.
FULVICIN P/G vs MYCOSTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubule-associated proteins, disrupting mitotic spindle formation and inhibiting fungal cell division.
Mycostatin (nystatin) is a polyene antifungal antibiotic that binds to ergosterol in the fungal cell membrane, forming pores that increase membrane permeability, leading to leakage of intracellular contents and cell death.
250 mg orally twice daily for tinea infections; 500 mg orally twice daily for onychomycosis. Administer with a fatty meal to enhance absorption.
Nystatin suspension: 400,000-600,000 units (4-6 mL) orally four times daily for 7-14 days. Nystatin pastilles: 200,000-400,000 units (1-2 pastilles) orally four to five times daily for 7-14 days.
None Documented
None Documented
Terminal elimination half-life: 9–24 hours (mean ~16 hours). Clinical context: prolonged half-life allows once-daily dosing; steady-state achieved within 2–3 days.
Not applicable (nystatin is not absorbed systemically; no meaningful plasma half-life exists). For reference, if absorbed, the terminal half-life would be approximately 4-6 hours, but this is not clinically relevant.
Renal (largely unchanged, <1% as metabolites); biliary/fecal (minor). Approximately 36% of a dose is excreted in urine within 6 hours, and up to 50% within 72 hours.
Nystatin is not absorbed from the gastrointestinal tract, skin, or mucous membranes. After oral administration, virtually all of the drug is excreted unchanged in feces. Renal excretion is negligible (<0.1%).
Category C
Category C
Antifungal
Antifungal